Drug Trial Radar · NCT00550238
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Last checked: Nov 20, 2026Latest source record: Jun 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
459
Actual
Start
Jul 2007
Primary completion
May 30, 2018
Study completion May 30, 2018
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
Conditions
- Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)Drug
Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)Time frame: From first to last study drug dose plus 30 days
Locations
135 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Gilbert, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Berkeley, California
Site not named
Carson, California
Site not named
Fountain Valley, California
Site not named
Fresno, California
Site not named
Irvine, California
Site not named
La Habra, California
Site not named
La Jolla, California
Site not named
Laguna Hills, California
Site not named
Loma Linda, California
Site not named
Oxnard, California
Site not named
Pasadena, California
Site not named
Reseda, California
Site not named
Sunnyvale, California
Site not named
Ventura, California
Site not named
Englewood, Colorado
Site not named
Danbury, Connecticut
Site not named
Fairfield, Connecticut
Site not named
Farmington, Connecticut
Site not named
Boca Raton, Florida
Site not named
Bradenton, Florida
Site not named
Deerfield Beach, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Naples, Florida
Site not named
Orlando, Florida
Site not named
Ormond Beach, Florida
Site not named
Panama City, Florida
Site not named
Pompano Beach, Florida
Site not named
Port Charlotte, Florida
Site not named
Sarasota, Florida
Site not named
St. Petersburg, Florida
Site not named
Tampa, Florida
Site not named
Augusta, Georgia
Site not named
Decatur, Georgia
Site not named
Glenview, Illinois
Site not named
Springfield, Illinois
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.